Superficial Vein Disease

Superficial Venous Disease III

Friday, October 14, 2022

2:30 PM – 4:00 PM US CDT

Location: Hyatt Regency, Celestin A / B/ C

CE: 1.5

Program Chair(s)

MICHAEL DI IORIO, MD, FAVLS, RPVI, RVT, RPhS

CEO/ Medical Director
South Austin Vein Center
Austin, Texas

I do not have any relevant financial / non-financial relationships with any proprietary interests.
Jeffery Schoonover, MD, RPVI, DABVLM, FAVLS

Chief Medical Officer, Indiana Vein Specialists
Indiana Vein Specialists
Fishers, IN

Venclose (Self) : Consultant/Advisory Board (Products and Services: Consultant - Training)

Participants should be aware of the following financial/non-financial relationships:

MICHAEL M. DI IORIO, MD, FAVLS, RPVI, RVT, RPhS: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Jeffery P. Schoonover, MD, RPVI, DABVLM, FAVLS: Venclose (Self) : Consultant/Advisory Board (Products and Services: Consultant - Training)

This year's Superficial Venous Disease sessions will cover three separate areas, with the third and final session being devoted to a review of superficial venous disease treatment guidelines and practice considerations in the era of COVID-19. This session will have relevant information for all levels of superficial venous care, but sure to provoke additional thought and discussion for the experienced provider.

Learning Objectives:

Upon completion, the participant will be able to successfully demonstrate understanding of the updated AVLS/SVS/AVF Guidleines of Superficial Venous Disease Treatment
Upon completion, the participant will be able to successfully demonstrate understanding of state of current evidence regarding diagnosis and treatment of endovenous heat induced thrombosis (EHIT)
Upon completion, the participant will be able to successfully demonstrate understanding of the updated anatomy and clinical implications of the Anterior Accessory Saphenous Vein
Upon completion, the participant will be able to successfully demonstrate understanding of the updated hematologic considerations in the era of COVID-19 and impact on patient receiving venous treatment
Upon completion, the participant will be able to successfully demonstrate understanding of benchmarking Interventions for the practice variability and application to procedural costs for endovenous thermal ablation

Presentations:

2:30 PM – 4:00 PM US CDT

Superficial Venous Disease III
Program Chair: MICHAEL M. DI IORIO, MD, FAVLS, RPVI, RVT, RPhS – South Austin Vein Center
Program Chair: Jeffery P. Schoonover, MD, RPVI, DABVLM, FAVLS – Indiana Vein Specialists
2:30 PM – 2:31 PM US CDT

Superficial Venous Disease III - Welcome
Program Chair: Jeffery P. Schoonover, MD, RPVI, DABVLM, FAVLS – Indiana Vein Specialists
Program Chair: MICHAEL M. DI IORIO, MD, FAVLS, RPVI, RVT, RPhS – South Austin Vein Center
2:31 PM – 2:45 PM US CDT

Review of Updated guidelines on Superficial Venous Disease Treatment
Faculty: Suman Wasan, MD – UNC Chapel Hill
2:45 PM – 3:00 PM US CDT

EHIT Update
Faculty: Robert L. Worthington-Kirsch, MD, FSIR, FCIRSE, FAVLS, RVT, RPVI, RPhS – United Vein and Vascular Centers
3:00 PM – 3:15 PM US CDT

Anatomy and Clinical Implications of the Anterior Accessory Saphenous Vein
Faculty: Marlin W. Schul, MD, RVT, FAVLS, DABLM, DFAVF
3:15 PM – 3:45 PM US CDT

Hematologic Considerations in the Vein Clinic and in Era of COVID-19
Faculty: Joseph E. Spahr, MD – INDIANA VEIN SPECIALISTS
3:45 PM – 4:00 PM US CDT

Advocacy Update-benchmarking Intervention for the Practice Variability/costs for Endovenous Thermal Ablation
Faculty: Margaret Mann, MD, FAAD, FAVLS – Innova Dermatology